<DOC>
	<DOC>NCT01960790</DOC>
	<brief_summary>This investigation will be conducted to obtain the following information regarding the use of Adalimumab 40mg Syringe 0.8mL for Subcutaneous Injection in patients with Intestinal Behcet's Disease. 1. Incidence and conditions of occurrence of adverse reactions in clinical practice 2. Factors likely to affect the safety and effectiveness</brief_summary>
	<brief_title>Special Investigation in Patients With Intestinal Behcet's Disease (All Case Investigation)</brief_title>
	<detailed_description />
	<mesh_term>Behcet Syndrome</mesh_term>
	<criteria>All patients who receive Adalimumab for the treatment of Intestinal Behcet's disease (not sufficiently responsive to existing therapies, e.g. steroids, immunomodulator) Contraindications according to the Package Insert include patients who have any of the following: serious infections tuberculosis a history of hypersensitivity to any ingredient of Humira® demyelinating disease or a history of demyelinating disease congestive cardiac failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Humira®</keyword>
	<keyword>Behcet's Disease</keyword>
	<keyword>Adalimumab</keyword>
</DOC>